Quote:

---

dostarlimab gets 'star' treatment on cnn -- imagine the coverage about LL!

---

Dostarlimab is stellar in mis-match repair deficient cancers. Most likely because in mis-match repair there's going to be a high level of mutated tumor cells and most of those mutations are going to have a negative effect on cell survival. Those tumor cells will also be more likely to be recognized by the immune system as "other". What's stopping the immune system from destroying them is PD-1/PD-L1 which tells the immune system to not destroy them. Dostarlimab blocks PD-L1 from binding to PD-1 which stops the do not kill signal from being activated. Leronlimab downregulates PD-1 and PD-L1.